Zay Oo

Dr. Zay Oo


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2014 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
YLYao Li
Yao Li
KKKarthikeyan Kandasamy
Karthikeyan Kandasamy
JCJacqueline Kai Chin Chuah
Jacqueline Kai Chin Chuah
YLYue Ning Lam
Yue Ning Lam
WTWei Seong Toh
Wei Seong Toh
DZDaniele Zink
Daniele Zink

1 December 2011 in Biomaterials
Verified
Journal Article
Closed access
ZOZay Oo
Zay Oo
RDRensheng Deng
Rensheng Deng
MHMin Hu
Min Hu
MNMing Ni
Ming Ni
KKKarthikeyan Kandasamy
Karthikeyan Kandasamy
DZDaniele Zink
Daniele Zink

1 January 2013 in Toxicology Research
Verified
Journal Article
Open access
PDF file
YLYao Li
Yao Li
ZOZay Oo
Zay Oo
SCShu Yung Chang
Shu Yung Chang
PHPeng Huang
Peng Huang
KEKim Guan Eng
Kim Guan Eng
DZDaniele Zink
Daniele Zink
The kidney is one of the major target organs for drug-induced toxicity. The renal proximal tubule is frequently affected due to its roles in drug tran

11 February 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LBLewis D. Blackman
Lewis D. Blackman
ZOZay Oo
Zay Oo
YQYue Qu
Yue Qu
PGPathiraja A. Gunatillake
Pathiraja A. Gunatillake
PCPeter Cass
Peter Cass
KLKatherine E. S. Locock
Katherine E. S. Locock

1 December 2015 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
Brian GabrielliBrian Gabrielli
Brian Gabrielli
FBFawzi Bokhari
Fawzi Bokhari
MRMax V. Ranall
Max V. Ranall
ZOZay Oo
Zay Oo
ASAlexander J. Stevenson
Alexander J. Stevenson
NMNigel McMillan
Nigel McMillan
Human papillomavirus (HPV) is the causative agent in cervical cancer. HPV oncogenes are major drivers of the transformed phenotype, and the cancers remain addicted to these oncogenes. A screen of the human kinome has identified inhibition of Aurora kinase A (AURKA) as being synthetically lethal on the background of HPV E7 expression. The investigational AURKA inhibitor MLN8237/Alisertib selectively promoted apoptosis in the HPV cancers. The apoptosis was driven by an extended mitotic delay in the Alisertib-treated HPV E7–expressing cells. This had the effect of reducing Mcl-1 levels, which is destabilized in mitosis, and increasing BIM levels, normally destabilized by Aurora A in mitosis. Overexpression of Mcl-1 reduced sensitivity to the drug. The level of HPV E7 expression influenced the extent of Alisertib-induced mitotic delay and Mcl-1 reduction. Xenograft experiments with three cervical cancer cell lines showed Alisertib inhibited growth of HPV and non-HPV xenografts during treatment. Growth of non-HPV tumors was delayed, but in two separate HPV cancer cell lines, regression with no resumption of growth was detected, even at 50 days after treatment. A transgenic model of premalignant disease driven solely by HPV E7 also demonstrated sensitivity to drug treatment. Here, we show for the first time that targeting of the Aurora A kinase in mice using drugs such as Alisertib results in a curative sterilizing therapy that may be useful in treating HPV-driven cancers. Mol Cancer Ther; 14(12); 2753–61. ©2015 AACR.

14 June 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ZOZay Oo
Zay Oo
ASAlexander J. Stevenson
Alexander J. Stevenson
MPMartina Proctor
Martina Proctor
SDSheena M. Daignault
Sheena M. Daignault
SWSebastian Walpole
Sebastian Walpole
Brian GabrielliBrian Gabrielli
Brian Gabrielli
Purpose: Checkpoint kinase 1 inhibitors (CHEK1i) have single-agent activity in vitro and in vivo. Here, we have investigated the molecular basis of this activity. Experimental Design: We have assessed a panel of melanoma cell lines for their sensitivity to the CHEK1i GNE-323 and GDC-0575 in vitro and in vivo. The effects of these compounds on responses to DNA replication stress were analyzed in the hypersensitive cell lines. Results: A subset of melanoma cell lines is hypersensitive to CHEK1i-induced cell death in vitro, and the drug effectively inhibits tumor growth in vivo. In the hypersensitive cell lines, GNE-323 triggers cell death without cells entering mitosis. CHEK1i treatment triggers strong RPA2 hyperphosphorylation and increased DNA damage in only hypersensitive cells. The increased replication stress was associated with a defective S-phase cell-cycle checkpoint. The number and intensity of pRPA2 Ser4/8 foci in untreated tumors appeared to be a marker of elevated replication stress correlated with sensitivity to CHEK1i. Conclusions: CHEK1i have single-agent activity in a subset of melanomas with elevated endogenous replication stress. CHEK1i treatment strongly increased this replication stress and DNA damage, and this correlated with increased cell death. The level of endogenous replication is marked by the pRPA2Ser4/8 foci in the untreated tumors, and may be a useful marker of replication stress in vivo. Clin Cancer Res; 24(12); 2901–12. ©2018 AACR.